Table 3.
Second-line tyrosine kinase inhibitors following immune checkpoint inhibitors in patients with metastatic renal cell carcinoma
| Author (year) | Design | Treatment | n | Median follow-up (months) | ORR (%) | Median PFS (months) |
|---|---|---|---|---|---|---|
| Present study | Phase II, prospective, single arm | Sunitinib | 21 | 15.0 | 19 | 5.6 |
| Auvray et al. (2019)9 | Retrospective | Sunitinib Axitinib |
17 8 |
22.0 | NR | 8 7 |
| Wells et al. (2021)17 | Retrospective | Sunitinib | 102 | NR | 22.5 | NR (TTD 5.4 months) |
| Ornstein et al. (2019)12 | Phase II, prospective, single arm | Axitinib | 40 | 8.7 | 45 | 8.8 |
| McGregor et al. (2020)14 | Retrospective | Cabozantinib | 86 | 12.0 | 36 | 6.5 |
| Iacovelli et al. (2020)24 | Retrospective Third line and beyond |
Cabozantinib | 84 (75 for ORR) |
NR | 52 | 11.5 |
| Procopio et al. (2021)26 | Phase II, prospective (n = 30) and retrospective (n = 19) | Cabozantinib | 48 | 8.0 | 43 | 9.3 |
| Cao et al. (2020)15 | Retrospective | Pazopanib | 182 (second line) | NR | NR | 16 |
| Powles et al. (2020)25 | Phase II, prospective, single arm | Pazopanib | 47 (second line) | NR | NR | 12 |
| Pal et al. (2020)16 | Phase II, randomized, noninferiority trial | Lenvatinib 14 mg Lenvatinib 18 mg |
343 (FAS) | ? | 32.1a 34.8a |
11.1 14.7 |
| Rini et al. (2019)5 | Phase III, randomized, open-label trial Third line |
Tivozanib Sorafenib |
175 175 |
19.0 | 18 8 |
5.6 3.9 |
FAS, full analysis set; NR, not reported; ORR, objective response rate; PFS, progression-free survival; TTD, time to treatment discontinuation.
a
Investigator assessment.